Table 2 Second-line chemotherapy regimens.

From: Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma

Treatment

LCNEC (n = 39)

SCLC (n = 431)

n (%)

n (%)

AMR

24 (61.5)

208 (48.3)

CDDP/CBDCA + ETP

3 (7.7)

97 (22.5)

CPT-11

3 (7.7)

18 (4.2)

DTX

3 (7.7)

0 (0.0)

NGT

1 (2.6)

26 (6.0)

PEI

1 (2.6)

24 (5.6)

CBDCA + PTX

1 (2.6)

23 (5.3)

PI

1 (2.6)

16 (3.7)

PTX

1 (2.6)

13 (3.0)

S-1

1 (2.6)

0 (0.0)

GEM

0 (0.0)

2 (0.5)

nab-PTX

0 (0.0)

1 (0.2)

CBDCA + nab-PTX

0 (0.0)

1 (0.2)

Investigation drugs

0 (0.0)

2 (0.5)

  1. AMR amrubicin, CDDP cisplatin, CBDCA carboplatin, ETP etoposide, CPT-11 irinotecan, DTX docetaxel, GEM gemcitabine, NGT topotecan, PEI cisplatin, etoposide, and irinotecan, PI cisplatin and irinotecan, PTX paclitaxel.
Back to article page